Endologix Inc. (NASDAQ:ELGX) has received a consensus recommendation of “Buy” from the thirteen ratings firms that are covering the stock. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and nine have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $13.64.
Several research analysts have issued reports on the stock. Canaccord Genuity reissued a “buy” rating on shares of Endologix in a research report on Tuesday, July 12th. RBC Capital Markets downgraded shares of Endologix from an “outperform” rating to a “sector perform” rating and lowered their price objective for the stock from $17.00 to $12.00 in a research report on Wednesday, August 3rd. BTIG Research reissued a “buy” rating and set a $16.00 price objective on shares of Endologix in a research report on Wednesday, August 3rd. Royal Bank Of Canada downgraded shares of Endologix from an “outperform” rating to a “sector perform” rating and lowered their price objective for the stock from $17.00 to $12.00 in a research report on Wednesday, August 3rd. Finally, Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $15.00 target price on shares of Endologix in a report on Wednesday, August 3rd.
Shares of Endologix (NASDAQ:ELGX) opened at 12.87 on Thursday. The stock’s market cap is $1.06 billion. The company’s 50-day moving average is $12.49 and its 200 day moving average is $11.98. Endologix has a 52 week low of $6.51 and a 52 week high of $14.50.
Endologix (NASDAQ:ELGX) last issued its quarterly earnings data on Tuesday, August 2nd. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.20) by $0.07. Endologix had a negative net margin of 82.39% and a negative return on equity of 41.88%. The company had revenue of $51 million for the quarter, compared to the consensus estimate of $46.30 million. During the same period last year, the firm posted ($0.18) EPS. Endologix’s revenue for the quarter was up 29.1% on a year-over-year basis. Analysts forecast that Endologix will post ($0.74) earnings per share for the current fiscal year.
In other Endologix news, VP Jose A. Lima sold 4,710 shares of Endologix stock in a transaction dated Friday, August 19th. The shares were sold at an average price of $11.68, for a total transaction of $55,012.80. Following the completion of the transaction, the vice president now owns 42,594 shares in the company, valued at $497,497.92. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Michael V. Chobotov sold 14,000 shares of Endologix stock in a transaction dated Friday, August 5th. The stock was sold at an average price of $12.40, for a total transaction of $173,600.00. Following the transaction, the insider now owns 189,269 shares of the company’s stock, valued at approximately $2,346,935.60. The disclosure for this sale can be found here. Company insiders own 3.90% of the company’s stock.
Institutional investors have recently made changes to their positions in the company. Legal & General Group Plc boosted its position in shares of Endologix by 34.9% in the first quarter. Legal & General Group Plc now owns 12,570 shares of the company’s stock worth $106,000 after buying an additional 3,252 shares during the last quarter. Nomura Holdings Inc. acquired a new position in shares of Endologix during the second quarter worth about $128,000. OLD National Bancorp IN acquired a new position in shares of Endologix during the second quarter worth about $129,000. Teacher Retirement System of Texas boosted its position in shares of Endologix by 15.8% in the second quarter. Teacher Retirement System of Texas now owns 10,333 shares of the company’s stock worth $129,000 after buying an additional 1,407 shares during the last quarter. Finally, Villere ST Denis J & Co. LLC acquired a new position in shares of Endologix during the second quarter worth about $134,000.
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
Receive News & Ratings for Endologix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.